B-Balloon is involved in research and development in the Cardio Vascular field. The company develops unique Stents and Stent Delivery Systems (SDS) that allow the safe placement of Stents in Coronary Bifurcation and Ostial Lesions, which remains one of the biggest unresolved problems in Percutaneous Coronary Intervention (PCI).
Ostial lesions – lesions occurring at the origin of an artery – account for about 7% of all lesions treated. They are associated with difficult angiographic visualization and consequent difficulties in positioning and stabilizing stents at the appropriate location in the ostium. Inappropriate placement of stents, either too distal or too proximal to the ostium, is associated with numerous complications. B-Balloon’s ostial technologies provide solutions to physicians, enabling them to locate stents and balloons at the ostium easily and precisely, without need for extensive angiographic visualization or other complex manoeuvres. 
The company is in the process of developing ostial balloon and stent delivery systems. More information will become available as these projects evolve. On July 1, 2008, Medical Ventures Corp., a Canadian public company specializing in vascular and surgical devices, merged with Neovasc Medical Ltd. and B-Balloon Ltd., two peregrine portfolio companies, and formed Neovasc, Inc., which shall be focused on the development of product for the heart & vascular disease market. This transaction brought together each company’s strong intellectual property and outstanding product development capabilities with the management and infrastructure of an established medical device company.